Idiopathic Pulmonary Fibrosis Global Market Report 2023 – By Drug Type (Nintedanib, Pirfenidone, Other Drug Types), By Mode Of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action), By Route Of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Providers), By End Users (Hospitals and Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Generic musculoskeletal disorders drugs refer to the medication that plays a key role in managing musculoskeletal condition. They are used to relieve pain and stiffness in muscles and treat muscle spasms. The main treatment of generic musculoskeletal disorders drugs are medication, therapy, surgery, and others. Medication refers to a dose form with one or more active chemicals as well as potential inactive ones. These can be administered through oral, parenteral, and other routes for the treatment of osteoarthritis, rheumatoid arthritis, spondylarthritis, juvenile idiopathic arthritis, psoriatic arthritis, fibromyalgia, and other disorders. These are distributed via various channels such as hospital pharmacy, retail pharmacy, drug store, and online pharmacy. The global generic musculoskeletal disorders drugs market is segmented - 1) By Treatment Type: Medication, Therapy, Surgery, Other Treatment Types 2) By Route of Administration: Oral, Parenteral, Other Routes 3) By Disorder Type: Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy The global generic musculoskeletal disorders drugs market size is expected to grow from $0.05 billion in 2022 to $0.06 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global generic musculoskeletal disorders drugs market size is expected to grow to $0.07 billion in 2027 at a CAGR of 5.7%. The high prevalence of arthritis is expected to propel the growth of the generic musculoskeletal disorders drugs market going forward. Arthritis refers to the tenderness and swelling of joints along with the symptoms including joint pain and stiffness. Generic musculoskeletal disorders drugs help to relieve pain and stiffness in muscles and can treat muscle spasms in arthritis patients. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, by 2040, 78.4 million adults aged 18 years and older (25.9% of the total adult population) are expected to have doctor-diagnosed arthritis. Therefore, the high prevalence of arthritis is driving the growth of the generic musculoskeletal disorders drugs market. Major players in the generic musculoskeletal disorders drugs market are Pfizer Inc., Sanofi S.A., Eli Lilly And Company, Ampio Pharmaceuticals Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca Plc., Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics Plc., Procter & Gamble, Eisai Co. Ltd., Biogen Inc., and Sino Biopharmaceutical Limited. Strategic partnerships are a key trend gaining popularity in the generic musculoskeletal disorders drugs market. Many companies operating in the generic musculoskeletal disorders drugs market are undergoing partnerships to strengthen their position in the market. For instance, in December 2020, PostEra, a US-based biotechnology company, partnered with Pfizer Inc., a US-based pharmaceutical and biotechnology corporation. This partnership aims to introduce advanced machine learning for drug discovery. Further, in February 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, partnered with Alex Therapeutics, a Sweden-based digital therapeutics company. This new strategic business relationship offers patients evidence-based, clinically verified, and tailored digital therapeutics. In May 2020, Assertio Therapeutics Inc., a US-based specialty pharmaceutical company acquired Zyla Life Sciences for an undisclosed deal amount. With this acquisition, Assertio Therapeutics aims to focus on neurology, inflammation, and pain products, an assortment of non-steroidal anti-inflammatory medicines that are distinct. Zyla Life Sciences is a US-based producer and distributor of anti-inflammatory and pain medications operating in the generic musculoskeletal disorders drugs market. Asia-Pacific was the largest region in the generic musculoskeletal disorders drugs market in 2022. The regions covered in the global generic musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the generic musculoskeletal disorders drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The generic musculoskeletal disorders drugs market consists of sales of analgesics, oral non-steroidal anti-inflammatory drugs (NSAIDs), opioids, anti-neuropathic pain medications, corticosteroids, and disease modifying anti-rheumatic drugs (DMARDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The generic musculoskeletal disorders drugs market research report is one of a series of new reports from The Business Research Company that provides generic musculoskeletal disorders drugs market statistics, including generic musculoskeletal disorders drugs industry global market size, regional shares, competitors with a generic musculoskeletal disorders drugs market share, detailed generic musculoskeletal disorders drugs market segments, market trends and opportunities, and any further data you may need to thrive in the generic musculoskeletal disorders drugs industry. This generic musculoskeletal disorders drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tumour necrosis factor (TNF) inhibitor drugs refer to drugs that help stop inflammation. TNF inhibitors are used to treat inflammatory and autoimmune illnesses by suppressing the inflammatory response generated by TNF cytokines. The main types in the market of tumour necrosis factor (TNF) inhibitor drugs are humira, enbrel, remicade, simponi/simponi aria, cimzia, and biosimilars. Humira refers to a tumour necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. The route of administration is subcutaneous injection, intravenous injection. The distribution channels involved hospital pharmacies, retail pharmacies, and online pharmacies, that are to be used in rheumatoid arthritis, psoriasis, psoriatic arthritis, crohn’s disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa and others. The global tumor necrosis factor inhibitor drugs market is segmented - 1) By Product Type: Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars 2) By Route Of Administration: Subcutaneous Injection, Intravenous Injection 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By Application: Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Other Applications The global tumor necrosis factor inhibitor drugs market size is expected to grow from $41.23 billion in 2022 to $41.84 billion in 2023 at a compound annual growth rate (CAGR) of 1.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global tumor necrosis factor inhibitor drugs market size is expected to reach $43.88 billion in 2027 at a CAGR of 1.2%. The increasing prevalence of autoimmune illness is expected to propel the growth of the tumor necrosis factor inhibitor drugs market going forward. Autoimmune disorders are conditions in which the immune system of the body unintentionally targets and kills healthy human tissue. The tumor necrosis factor inhibitor drug is used in autoimmune disorders to stop inflammation if there is any pain or swelling or illness, these drugs block the action. It gives a booster to the immune system, makes it steady, and protects the body from inflammation. For instance, in June 2022, according to the Autoimmune Association, a US-based non-profit organization dedicated to autoimmune disease awareness, 4.7 million US men suffered from autoimmune disease 2022, representing 20% of all autoimmune disease patients. 31 million US people suffer 80-150 unique autoimmune diseases in 2022, it's expected to increase in the future. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the tumor necrosis factor inhibitor drugs market. Major players in the tumor necrosis factor inhibitor drugs market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Pfizer Inc., Merck & Co.Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Sanofi S.A, Celltrion Inc., HanAll Biopharma, AstraZeneca plc, ACROBiosystems, and Alomone Labs. Product innovations are a key trend in gaining popularity in the tumor necrosis factor inhibitor drugs market. Major companies operating in the tumor necrosis factor inhibitor drugs market are focused on developing innovative products to strengthen their position in the market. For instance, in December 2021, Pfizer Inc, a US-based company operating in tumor necrosis factor inhibitor drugs, launched XELJANZ. XELJANZ is intended to treat ankylosing spondylitis in those who haven't responded well to one or more TNF blockers. It has a unique treatment option for 'ankylosing spondylitis'(SA) that does not require an injection or an infusion to treat this debilitating and chronic immuno-inflammatory disease. XELJANZ works by blocking the action of Janus kinase enzymes, which are involved in inflammation. In April 2022, Samsung Biologics, a South Korea-based biotechnology company, acquired Samsungbioepis Co.Ltd. for $2.3 billion. Through this acquisition, Samsung Biologics is expected to accelerate Samsung Bioepis' biosimilar development capabilities and future performance in novel drug development, with improved autonomy and agility in business operations. Samsung bioepis Co.Ltd. is a South Korea-based biopharmaceutical company operating in tumor necrosis factor inhibitor drugs. North America was the largest region in the tumor necrosis factor inhibitor drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global tumor necrosis factor (TNF) inhibitors drugs market report during the forecast period. The regions covered in the global tumor necrosis factor (TNF) inhibitors drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the tumour necrosis factor (TNF) inhibitors drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The tumor necrosis factor (TNF) inhibitors drugs market consists of sales of enbrel, ereizi, inflectra, and renflexis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The tumour necrosis factor (TNF) inhibitor drugs market research report is one of a series of new reports from The Business Research Company that provides tumour necrosis factor (TNF) inhibitor drugs market statistics, including global market size, regional shares, competitors with a tumour necrosis factor (TNF) inhibitor drugs market share, detailed tumour necrosis factor (TNF) inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tumour necrosis factor (TNF) inhibitor drugs industry. This tumour necrosis factor (TNF) inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasma protein therapeutics refers to therapies derived from plasma and their recombinant analogs. It is used for the treatment of specific medical conditions by replacing missing or deficient proteins found in plasma, allowing recipients to live healthier and more productive lives. The main products of plasma protein therapeutics are immunoglobulin, albumin, coagulation factor, c1-esterase inhibitors, and other products. Immunoglobulin refers to a component of blood plasma that contains immunoglobulins or antibodies. These are administrated through different routes of administration including intravenous, and subcutaneous and are used for various applications such as primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema and other applications. The global plasma protein therapeutics market is segmented - 1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products 2) By Route Of Administration: Intravenous, Subcutaneous 3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications The global plasma protein therapeutics market size is expected to grow from $26.25 billion in 2022 to $28.11 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global plasma protein therapeutics market size is expected to reach $35.84 billion in 2027 at a CAGR of 6.3%. An increasing prevalence of autoimmune disorders is expected to propel the growth of the plasma protein therapeutics market going forward. An autoimmune disorder is a condition that emerges when the body's immune system attacks and destroys healthy body cells. Therapeutic plasma exchange is used to treat autoimmune diseases, which emerge when the body misidentifies a part of itself as foreign and produces proteins (known as autoantibodies) that attack the part of the body that is misidentified. For instance, in September 2021, according to Scientific American, a US-based science magazine, autoimmune diseases affect about 4% of the global population. Furthermore, in May 2020, according to the National Library of Medicine, a US-based biomedical library, autoimmunity diseases have a 2 to 1 prevalence rate for women. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the plasma protein therapeutics market going forward. Major players in the plasma protein therapeutics market are Octapharma AG, CSL Behring LLC, Grifols S.A, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion S.p.A., Shire PLC., LFB GROUP, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions B.V., Bio Products Laboratory Ltd., and MP Biomedicals LLC. Product innovations are a key trend gaining popularity in the plasma protein therapeutic gaining market. Major companies operating in the plasma protein therapeutic sector are focused on innovative products to gain a competitive advantage in the market. For instance, November 2021, Biognosys a Switzerland-based biotechnology company launched an innovative next-Generation blood biomarker discovery solution. The service is intended to assist researchers in deciphering the complexities of the blood proteome and unlocking unbiased discoveries for pharmaceutical and diagnostic development, as well as precision medicine. A unique feature of both solutions is Biognosys' Hyper Reaction Monitoring (HRMTM) technology and its optimized Liquid Chromatography-Mass Spectrometry (LC-MS) workflow. In April 2022, Grifols S.A, a Spain-based pharmaceutical, and chemical manufacturer acquired Tiancheng (Germany) Pharmaceutical Holdings AG for € 1.6 billion ($1.72 billion). This acquisition is expected to accelerate and expand Grifols' product portfolio, increase patient access to plasma therapies, and drive revenue growth and margin expansion. Biotest is a Germany-based healthcare company specializing in innovative hematology and clinical immunology and focused on developing, manufacturing, and marketing plasma proteins and biotherapeutic drugs. North America was the largest region in the plasma protein therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this global plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the plasma protein therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The plasma protein therapeutics market includes revenues earned by entities by providing therapy for liver disease and bleeding from trauma by using Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The plasma protein therapeutics market research report is one of a series of new reports from The Business Research Company that provides plasma protein therapeutics market statistics, including plasma protein therapeutics industry global market size, regional shares, competitors with a plasma protein therapeutics market share, detailed plasma protein therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the plasma protein therapeutics industry. This plasma protein therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Overactive bladder refers to a collection of symptoms that may affect how often a person pees and the urgency. Treatment includes changing certain behaviours and incorporating pelvic floor muscle exercises, and others to eliminate symptoms. Treatment can be helpful for relieving the symptoms of an overactive bladder and reducing episodes of urgent incontinence. The main types of diseases in overactive bladder treatment are idiopathic bladder overactivity and neurogenic bladder overactivity. Idiopathic bladder overactivity refers to an involuntary contraction of the bladder muscle that causes a sudden and urgent need to urinate and is treated by overactive bladder (OAB) treatment therapies with anticholinergics and beta-3 agonists. The diseases are treated by various therapies including anticholinergics, mirabegron, neurostimulation, intravesical instillation, and other therapies distributed by channels such as hospital pharmacies, drug stores, retail pharmacies, and online providers. The global overactive bladder treatment market is segmented - 1) By Diseases Type: Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity 2) By Therapy: Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation, Other Therapies 3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers The global overactive bladder treatment market size is expected to grow from $2.90 billion in 2022 to $3.01 billion in 2023 at a compound annual growth rate (CAGR) of 3.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global overactive bladder treatment market size is expected to reach $3.51 billion in 2027 at a CAGR of 3.9%. A rising geriatric population is expected to boost the growth of the overactive bladder treatment market going forward. The geriatric population refers to the population of people aged 65 and older. Geriatric patients are more vulnerable to urinary tract infections due to a variety of factors, such as decreased urine flow, an overactive bladder, an enlarged prostate, or kidney stones. This will propel demand for overactive bladder treatments. For instance, in February 2020, according to the United States Census Bureau, a US-based government agency responsible for collecting and publishing data about the population, economy, and geography, people aged 65 or older accounted for 56 million, or 17% of the total population in the USA. This population is expected to grow to 94 million by 2050, accounting for 23% of the total population. Therefore, the rising geriatric population is driving the growth of the overactive bladder treatment market. Major players in the overactive bladder treatment market are AbbVie Inc., Astellas Pharma Inc., Laborie, Endo International Plc., Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson Services Inc., Medtronic Plc., Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Limited, Cogentix Medical Inc., Dr. Reddy’s Laboratories Ltd., Sumitomo Pharma Co. Ltd, Sun Pharmaceutical Industries Ltd., and Intas Pharmaceuticals Limited. Technological advancements are a popular trend in the overactive bladder treatment market. Major companies operating in the market are introducing advanced products integrated with latest technologies to sustain their position in the market. For instance, in August 2020, Medtronic Plc, an Ireland-based medical technology company, launched the New InterStim Micro Neurostimulator for sacral neuromodulation (SNM) therapy. The InterStim Micro neurostimulator boasts the innovative SureScan MRI technology, allowing for complete MRI conditional scans of the entire body. Sacral neuromodulation utilizes electrical impulses to enhance bladder and bowel control by directly modulating nerve activity in the lower back. This method normalizes communication between the bladder and the brain, offering better control of symptoms. In March 2021, Sumitovant Biopharma, a US-based biopharmaceutical company, acquired Urovant Sciences Ltd. for an undisclosed amount. This acquisition is expected to provide capital for long-term business objectives and ensure focus on Sumitovant’s mission to develop and commercialize innovative therapies for its patients. Urovant Sciences Ltd. is a Switzerland-based clinical-stage biopharmaceutical company that is focused on developing and commercializing innovative therapies for urologic conditions, including overactive bladder (OAB) treatments. North America was the largest region in the overactive bladder treatment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global overactive bladder treatment market report during the forecast period. The regions covered in the global overactive bladder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the overactive bladder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The overactive bladder treatment market consists of revenues earned by entities by providing treatments such as behavioral therapies, nerve stimulation, and percutaneous tibial nerve stimulation (PTNS). The market value includes the value of related goods sold by the service provider or included within the service offering. The overactive bladder treatment market also includes sales of medications used in providing overactive bladder treatment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The overactive bladder treatment market research report is one of a series of new reports from The Business Research Company that provides overactive bladder treatment market statistics, including overactive bladder treatment industry global market size, regional shares, competitors with an overactive bladder treatment market share, detailed overactive bladder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the overactive bladder treatment industry. This overactive bladder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmonary arterial hypertension refers to a form of excessive blood pressure that harms the right side of the heart and the arteries in the lungs. The lungs' artery walls become constricted and rigid due to this long-lasting, incurable condition. The pulmonary arterial hypertension drugs relax the muscles in the walls of the blood vessels, increase the blood flow through the lungs, or reverse the effect of the substance in the walls of blood vessels that causes them to narrow. The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/subcutaneous, and inhalational modes and distributed through retail and online channels. The global pulmonary arterial hypertension market is segmented - 1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators 2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational 3) By Distribution channel: Retail, Online The global pulmonary arterial hypertension market size will grow from $7.05 billion in 2022 to $7.63 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the pulmonary arterial hypertension is expected to grow to $10.47 billion in 2027 at a CAGR of 8.2%. The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalisation of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500–1000 new cases each year, and Europe is expected to have similar incidence rates. Major players in the pulmonary arterial hypertension market are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc., Natco Pharma Ltd., Zydus Pharmaceutical USA, and Liquidia Technologies Inc. Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drug sector are focusing on developing new medicines to improve and cure these diseases. For instance, in April 2021, United Therapeutics Corporation, a US-based biotechnology company, launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Tyvaso is an inhalation solution that helps patients enhance their exercise abilities, reduce breathing difficulties, have a low tolerance for exertion, and have a higher mortality rate. In September 2021, Merck Group, a German-based multinational science and technology company that specialises in healthcare and life sciences solutions, acquired Acceleron Pharma for $11 billion. Through this acquisition, Merck will obtain ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication, and also puts the company at the forefront of rare disease-focused companies. Acceleron Pharma is a US-based company committed to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions such as pulmonary arterial hypertension. North America was the largest region in the pulmonary arterial hypertension market in 2022. The regions covered in the pulmonary arterial hypertension market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The pulmonary arterial hypertension market research report is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunoglobins refer to glycoproteins, often known as antibodies, that are created by plasma cells (white blood cells). They play a crucial role in the immune response by selectively identifying and attaching to specific antigens, like viruses or bacteria, and assisting in their eradication. The main types of products in immunoglobulins are IGG, IGA, IGM, IGE, and IGD. Immunoglobulin G (IGG) is the primary stimulator of humoral immunity in extracellular fluids such as blood, lymph, and saliva. The immunoglobulins are delivered using the intravenous mode of delivery, subcutaneous mode of delivery and are used in hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disease, myasthenia gravis, idiopathic thrombocytopenic purpura (ITP), others. The global immunoglobulins market is segmented - 1) By Product: IGG, IGA, IGM, IGE, IGD. 2) By Mode Of Delivery: Intravenous Mode of Delivery, Subcutaneous Mode of Delivery 3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications The global immunoglobulins market size will grow from $15.89 billion in 2022 to $17.16 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The immunoglobulins market size is expected to grow to $24.1 billion in 2027 at a CAGR of 8.9%. The increasing geriatric population drives the growth of the immunoglobulins market. The geriatric population is at high risk of infectious diseases and auto-immune diseases. The immunoglobulin test determines the body's ability to produce antibodies that protect it from bacteria, viruses, and allergies. According to the United Nations department of economic and social affairs (UN DESA), in 2020, the number of people aged over 65 was 727 million globally. By 2050, this figure is expected to have more than doubled, reaching over 1.5 billion people. The aging population is expected to rise from 9.3% in 2020 to 16% in 2050. Thus, the increasing geriatric population is expected to increase the demand for the immunoglobulins market during the forecast period. Major players in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma, China Biologic Products Inc., Kedrion S.p.A., LFB group, Biotest AG, Sanquin, ADMA Biologics, Option Care Enterprises, and Shanghai Raas Blood Products Co. Ltd. The launch of new offices and laboratories to boost research and development activities is shaping the immunoglobulins market. Major companies operating in the immunoglobulins sector are focused on opening new laboratories for immunoglobulins to enhance the platform technology, pipeline development, and manufacturing capabilities. For instance, in February 2021, VectorY, a fully integrated gene therapy firm, has opened offices and laboratories in the Netherlands to develop novel vectorized antibodies for muscular and neurological illnesses. In this laboratory, VectorY creates exclusive and collaborative projects based on a revolutionary AAV platform and antibody-based targeted degradation technology. The company is developing a pipeline of new vectorized antibodies to treat muscle and CNS illnesses, to enhance delivery, durability, and accessibility of specific tissues and cells, to overcome the limits of present therapies. In June 2020, CSL Behring, a US-based biopharmaceutical company acquired Vitaeris Inc., for an undisclosed amount. This acquisition accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for the treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio. Vitaeris Inc., is a US-based clinical-stage biotechnology company. North America was the largest region in the immunoglobulins market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the immunoglobulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The immunoglobins market consists of sales of antibodies, glycoproteins, and antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The immunoglobulins market research report is one of a series of new reports from The Business Research Company that provides immunoglobulins market statistics, including immunoglobulins industry global market size, regional shares, competitors with a immunoglobulins market share, detailed immunoglobulins market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulins industry. This immunoglobulins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastroparesis is a medical condition characterized by the impairment or weakening of the stomach muscles, resulting in delayed emptying of stomach contents into the small intestine. Gastroparesis is treated by medications to stimulate stomach emptying and manage underlying conditions, and surgical interventions. The main treatment modalities of gastroparesis are medications, dietary modifications, medical devices, and others. Medications are substances that work by interacting with the body's biological processes to produce a desired effect. Medications such as prokinetic drugs, antiemetics, botulinum toxin injections, antidepressants, and others are used to diagnose, treat, cure, or prevent gastroparesis. These are used for the treatment of idiopathic, diabetic, post-surgical, and others in pediatric and adult patients. These are distributed by retail pharmacies, hospital pharmacies, and others, which are used by hospitals and clinics, ambulatory surgical centers, and home care settings. The global gastroparesis market is segmented - 1) By Treatment Modality: Medications, Dietary Modifications, Medical Devices, Other Therapies 2) By Gastroparesis Type: Idiopathic, Diabetic, Post- Surgical, Other Types 3) By Patient Demographics: Pediatric Gastroparesis, Adult Gastroparesis 4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels 5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings The global gastroparesis market is expected to grow from $6.08 billion in 2022 to $6.44 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gastroparesis market is expected to reach $7.77 billion in 2027 at a CAGR of 4.8%. The increasing prevalence of gastroparesis is expected to propel the growth of the gastroparesis market. Gastroparesis is a medical condition that stops or delays food movement from the stomach to the small intestine. Hypothyroidism, autoimmune diseases, injury to the vagus nerve, and viral stomach infections cause gastroparesis. Gastroparesis medicine tightens and contracts the muscles in the stomach wall and improves gastric emptying. For instance, in 2021, according to a research study published by Practice Update, a Netherlands-based online publisher of research articles, in 2021 the overall prevalence rate of gastroparesis was 267.7 per 100,000 persons in the US. The prevalence rate of definite gastroparesis was 21.5 per 100,000 persons. As a result, the increasing prevalence of gastroparesis is driving the growth of gastroparesis treatment. Major players in the gastroparesis market are Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk AS, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical co. ltd, ReGenXBio Inc., ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Orexo AB, Theravance Biopharma Inc., RQI Partners LLC., RedHill Biopharma Ltd., Synthorx Inc., Valeant Pharmaceuticals International Inc., CinRx Pharma LLC., Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., and Neurogastrx Inc. The development of an advanced drug for the treatment of gastroparesis is a key trend gaining popularity in the gastroparesis market. Major companies operating in the gastroparesis market are developing innovative drug formulations to sustain their position in the market. For instance, in June 2020, Evoke Pharma, a US-based pharmaceuticals company, received approval for its metoclopramide nasal spray from the US Food and Drug Administration, a US-based health regulatory agency for treating gastroparesis. The new formulation is the first and only nasally administered medication for treating acute and recurrent diabetic gastroparesis. In May 2020, AbbVie Inc., a US-based pharmaceutical company, acquired Allergan plc for an undisclosed amount. The acquisition diversified AbbVie's presence in newer therapeutic areas and helped it reach a broader consumer base. Allergan plc is an Ireland-based pharmaceutical company that develops drugs for treating gastroparesis. North America was the largest region in the gastroparesis market in 2022. The regions covered in gastroparesis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastroparesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The gastroparesis market consists of sales of metoclopramide, domperidone, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The gastroparesis research report is one of a series of new reports from The Business Research Company that provides gastroparesis market statistics, including the gastroparesis industry's global market size, regional shares, competitors with gastroparesis market share, detailed gastroparesis market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis industry. This gastroparesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Constipation treatment refers to the numerous methods and measures taken to alleviate and manage the ailment, which is characterized by irregular or difficult bowel motions and frequently hard or dry stools. It is used to examine the rectum and lower, or sigmoid, colon and to treat constipation. The main types of therapeutics for constipation treatment are laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C (guanylate cyclase-c) agonists, and others. Laxatives refer to a material that facilitates the release of intestinal feces in humans that are used in constipation treatment to improve stool size, frequency, and motility. These are used for chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC) diseases and are distributed by various channels including hospital pharmacies, retail pharmacies, and online pharmacies. The global constipation treatment market is segmented - 1) By Therapeutic Types: Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C (Guanylate Cyclase-C) Agonists, Other Therapeutics 2) By Disease Type: Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome With Constipation (IBS-C), Opioid-Induced Constipation (OIC) 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global constipation treatment market is expected to grow from $10.26 billion in 2022 to $10.95 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The constipation treatment market is expected to reach $13.97 billion in 2027 at a CAGR of 6.3%. Growing consumption of fast food is expected to propel the growth of the constipation treatment market going forward. Fast food refers to hot food that a customer cooks or orders from a specific sort of restaurant and is provided shortly. Fast foods are low in fiber and high in fat and salt, so they can lead to constipation. For instance, as per the report published by the Census and Statistics Department, a Hong Kong-based economic statistics provider, when comparing the entire year of 2021 to the entire year of 2020, total sales at fast food restaurants in Hong Kong, increased by 6.4% in volume and 8.6% in value. Therefore, the growing consumption of fast food is driving the growth of the constipation treatment market. Major players in the constipation treatment market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Fresenius Kabi AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Bausch Health Companies Inc., Eisai Co. Ltd., Shionogi & Co. Ltd., Mallinckrodt Plc, Salix Pharmaceuticals Inc., Prestige Consumer Healthcare Inc., Taiho Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals NV, Ferring Pharmaceuticals, RedHill Biopharma Ltd., Probi AB, and 4D Pharma plc. Product innovation is a key trend gaining popularity in the constipation treatment market. Companies operating in the constipation treatment market are working on new product innovations to sustain their position in the market. For instance, in April 2022, Ardelyx, a US-based biopharmaceutical company, launched IBSRELA, a first-in-class treatment for irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is the first innovative mechanism therapy for irritable bowel syndrome with constipation (IBS-C) to be developed in more than ten years, and it provides a significant new treatment option for constipation, bloating, and stomach pain that are symptoms of this crippling disorder. In March 2023, Ipsen, a France-based pharma company acquired Albireo Pharma Inc. for an undisclosed amount. Through the acquisition of Albireo, Ipsen strengthens its portfolio in rare diseases. Albireo Pharma Inc. is a US-based biotech company developing drugs for the treatment of chronic constipation. North America was the largest region in the constipation treatment market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the constipation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The constipation treatment market consists of sales of polyethylene glycol, bisacodyl, tegaserod, lubiprostone, and senna. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The constipation treatment market research report is one of a series of new reports from The Business Research Company that provides constipation treatment market statistics, including constipation treatment industry global market size, regional shares, competitors with a constipation treatment market share, detailed constipation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the constipation treatment industry. This constipation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.